We Advance, Together
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Immune engager therapies, according to a retrospective study of real-world patients, had the best rates of responses and progression-free survival in patients with multiple myeloma whose disease relapsed after treatment with idecabtagene vicleucel.
Label Expansion for Oral Ibrutinib Suspension Gets FDA Approval
The label expansion for ibrutinib with an oral suspension formulation has been approved by the FDA in all current indications including Waldenström macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, and chronic graft-versus-host disease.
Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should Be Lower
New research out of VCU Massey Comprehensive Cancer Center and VCU Health Pauley Heart Center indicates that survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event — including heart failure, heart attack or stroke — than the general public.
Mindfulness as Self-Care in Oncology Nursing May Also Improve Patient Care
An expert discussed how the benefits of mindfulness in patients with cancer can also be applied to oncology nurses.
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with lisocabtagene maraleucel experienced durable responses.
Opinion: Tinengotinib Shows Promise for Cholangiocarcinoma After FGFR Inhibitor Treatment
Oncology nurses can advocate for patients with cholangiocarcinoma to participate in on-going clinical trials with tinengotinib.
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
The antifungal prophylaxis azoles did not impact the safety and efficacy of ruxolitinib in patients with graft-vs-host disease.
Immunotherapy Produces ‘Unprecedented Results’ for Advanced Endometrial Cancer
During a Community Case Forum, Tiffany Bostwick, P.A., discussed how immunotherapy for advanced endometrial cancer has contributed to improved results compared with the previous standard of care.
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
Patients with GVHD treated with ruxolitinib plus belumosudil experienced an overall response rate of 55%, which may suggest an interaction between inflammatory pathways.
BLA for Datopotamab Deruxtecan Under FDA Review for Pretreated Advanced Nonsquamous NSCLC
The FDA is currently reviewing a BLA that seeks the approval of datopotamab deruxtecan as a therapeutic option for pretreated nonsquamous non–small cell lung cancer.
Ruxolitinib Cream Improves Body Surface Area in Cutaneous GVHD
Compared with placebo, ruxolitinib cream significantly improved body surface area in patients with cutaneous graft-vs-host disease in a phase 2 trial.
Brexu-cel Results in High Rates of CNS Remission in R/R B-Cell ALL
It may be feasible to use brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.
Liso-cel Improves Responses, Survival in High-Risk MCL
Liso-cel may be an effective treatment option for relapsed/refractory mantle cell lymphoma, including those with high-risk features who have limited treatment options.
Experience, Communication May Help Oncology Nurses Learn More About TIL Therapy in Advanced Melanoma
Two experts commented on ways oncology nurses can learn more about administering TIL therapy and how they can play a supportive role for patients receiving the treatment.
Lurbinectedin Provides Superior Risk/Benefit Ratio vs Topotecan in SCLC
Lurbinectedin confers greater activity with a superior safety profile when compared with topotecan in a subset of patients with small cell lung cancer.
Opinion: KRAS Mutations Provide Prognostic Insights and Expand Treatment Options
Oncology nurses can assist patients in understanding the significance of KRAS mutation testing and its treatment implications.
Bi-weekly Teclistamab Dosing Receives FDA Approval for Relapsed/Refractory Multiple Myeloma
A supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) has been approved by the FDA at a reduced dose of 1.5 mg/kg every 2 weeks for the treatment of patients with relapsed/refractory multiple myeloma who have maintained a complete response or greater for at least 6 months.
Tracking Hand Hygiene Adherence With Wearable Technology
Wearable technology can track hand hygiene protocol adherence, making wards more aware of their hand washing and sanitizing rates on a weekly basis.
Olaparib Shows Manageable AEs in Early Breast Cancer
Treatment-emergent symptoms were easily resolved after treatment with olaparib for BRCA1/2 high-risk HER2-negative breast cancer, as shown in a patient reported outcome analysis of the phase 3 OlympiA trial.
The New Process Checking System Makes Sure the Right Drugs Are Dispensed, Improving Patient Safety
SBRT Plus Standard of Care Improves PFS in Oligoprogressive NSCLC
Stereotactic ablative radiotherapy with standard-of-care therapy improved progression-free survival in patients with oligoprogressive non-small cell lung cancer, although the benefit was not seen in those with oligoprogressive breast cancer.
Sacituzumab Govitecan Plus Pembrolizumab Improves Responses in Bladder Cancer
All prespecified patient subgroups with metastatic urothelial cancer showed a clinical benefit with sacituzumab govitecan plus pembrolizumab in cohort 3 of the phase 2 TROPHY-U-01 trial.
AI-Powered Detection System for Skin Cancers Receives FDA Approval
The first real-time, non-invasive skin cancer evaluation system has received clearance from the FDA.
Tislelizumab Plus Chemo Improves Event-Free Survival in Stage II-IIIA NSCLC
The use of perioperative tislelizumab plus neoadjuvant chemotherapy has been supported by findings from the phase 3 RATIONALE-315 study as a treatment for resectable stage II to IIIA non–small cell lung cancer.
Osimertinib Receives Approval From FDA for EGFR-Mutated Locally Advanced or Metastatic NSCLC
The FDA approved osimertinib for use with platinum-based chemotherapy to treat patients with locally advanced or metastatic non-small cell lung cancer that harbor EGFR exon 19 deletions or exon 21 L858R mutations.
FDA Approves TIL Therapy for Unresectable or Metastatic Melanoma
Lifileucel is the first TIL therapy approved by the FDA for a solid tumor, specifically previously treated unresectable or metastatic melanoma.
Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors
A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.
Soquelitinib Receives FDA Orphan Drug Designation FDA for T-Cell Lymphoma
The FDA granted an orphan drug designation to soquelitinib for potential use in T-cell lymphoma.
FDA Approves Tepotinib for Metastatic NSCLC With MET Exon 14 Skipping Alterations
Tepotinib has received a traditional approval from the FDA for metastatic NSCLC with MET exon 14 skipping alterations, updating the previous accelerated approval from 2021.
2 Commerce Drive Cranbury, NJ 08512